Literature DB >> 20298811

Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B.

Wen-Juei Jeng1, I-Shyan Sheen, Yun-Fan Liaw.   

Abstract

BACKGROUND & AIMS: Acute exacerbations of chronic hepatitis B virus (HBV) infection can lead to hepatic decompensation. It is important to identify factors that predict the development of hepatic decompensation during exacerbation so that antiviral therapy can be initiated immediately.
METHODS: Acute exacerbation, defined by an abrupt increase in alanine aminotransferase (ALT) levels to >5-fold the upper limit of normal, occurred in 110 hepatitis B e antigen (HBeAg)-seropositive non-cirrhotic patients (138 episodes). The patients were monitored every 1 to 2 weeks for serum levels of ALT, bilirubin, albumin, and prothrombin. Sex, age, HBV genotype, ALT level, HBV viral load, and the causes (spontaneous or relapse from antiviral treatment) of exacerbation were included in multivariate logistic regression analyses. The receiver operating characteristic curve was used to identify the optimal cut-off value of serum HBV DNA level to identify patients at risk for decompensation.
RESULTS: Seven of the 138 episodes of acute exacerbation (5.1%) resulted in hepatic decompensation; serum HBV DNA level was the only significant risk factor (P = .003). The area under the receiver operating characteristic curve was 88.6% (P < .001). A serum HBV DNA cut-off value of 1.55 x 10(9) copies/mL predicted decompensation with a sensitivity of 85.7%, a specificity of 85.5%, a negative prediction value of 99.1%, and positive prediction value of 24.0%.
CONCLUSIONS: During acute exacerbation of HBeAg-positive chronic hepatitis B, a serum HBV DNA cut-off value of 1.55 x 10(9) copies/mL can be used to identify patients in need of immediate antiviral therapy. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20298811     DOI: 10.1016/j.cgh.2010.02.023

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  21 in total

1.  Score model for predicting acute-on-chronic liver failure risk in chronic hepatitis B.

Authors:  Fang-Yuan Gao; Yao Liu; Xiao-Shu Li; Xie-Qiong Ye; Le Sun; Ming-Fan Geng; Rui Wang; Hui-Min Liu; Xiao-Bing Zhou; Li-Li Gu; Yan-Min Liu; Gang Wan; Xian-Bo Wang
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

2.  Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection.

Authors:  Nami Mori; Fumitaka Suzuki; Yusuke Kawamura; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Masahiro Kobayashi; Satoshi Saito; Yoshiyuki Suzuki; Yasuji Arase; Kenji Ikeda; Mariko Kobayashi; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2012-02-29       Impact factor: 7.527

Review 3.  Natural history of chronic hepatitis B: phases in a complex relationship.

Authors:  Catherine M N Croagh; John S Lubel
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

Review 4.  Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis B.

Authors:  Pankaj Puri
Journal:  J Clin Exp Hepatol       Date:  2013-10-17

5.  Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B.

Authors:  Corinna Jen-Hui Pan; Hui-Lin Wu; Stephanie Fang-Tzu Kuo; Jia-Horng Kao; Tai-Chung Tseng; Chen-Hua Liu; Pei-Jer Chen; Chun-Jen Liu; Ding-Shinn Chen
Journal:  Hepatol Int       Date:  2011-07-16       Impact factor: 6.047

6.  Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation.

Authors:  Cyriac Abby Philips; Shiv Kumar Sarin
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

7.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.

Authors:  Yun-Fan Liaw; Jia-Horng Kao; Teerha Piratvisuth; Henry Lik Yuen Chan; Rong-Nan Chien; Chun-Jen Liu; Ed Gane; Stephen Locarnini; Seng-Gee Lim; Kwang-Hyub Han; Deepak Amarapurkar; Graham Cooksley; Wasim Jafri; Rosmawati Mohamed; Jin-Lin Hou; Wan-Long Chuang; Laurentius A Lesmana; Jose D Sollano; Dong-Jin Suh; Masao Omata
Journal:  Hepatol Int       Date:  2012-05-17       Impact factor: 6.047

8.  Nuclear export and import of human hepatitis B virus capsid protein and particles.

Authors:  Hung-Cheng Li; Er-Yi Huang; Pei-Yi Su; Szu-Yao Wu; Ching-Chun Yang; Young-Sun Lin; Wen-Chang Chang; Chiaho Shih
Journal:  PLoS Pathog       Date:  2010-10-28       Impact factor: 6.823

9.  Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure.

Authors:  Daxian Wu; Sainan Zhang; Zhongyang Xie; Ermei Chen; Qunfang Rao; Xiaoli Liu; Kaizhou Huang; Jing Yang; Lanlan Xiao; Feiyang Ji; Zhengyi Jiang; Yalei Zhao; Xiaoxi Ouyang; Danhua Zhu; Xiahong Dai; Zhouhua Hou; Bingjie Liu; Binbin Deng; Ning Zhou; Hainv Gao; Zeyu Sun; Lanjuan Li
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

10.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.